Study Detail

TitleNPM1_ex_vivo_CRISPR
Study TypeCancer Genomics
Abstract Acute myeloid leukaemia (AML) continues to have a very high mortality and its treatment has not changed for more than 20 years. Here, we propose to apply genomic-wide screens to directly identify therapeutic vulnerabilities of AML using AML cells lines with pre-defined somatic mutations. Our studies .. [more]
Description Acute myeloid leukaemia (AML) continues to have a very high mortality and its treatment has not changed for more than 20 years. Here, we propose to apply genomic-wide screens to directly identify therapeutic vulnerabilities of AML using AML cells lines with pre-defined somatic mutations. Our studies .. [more]
Center NameThe Wellcome Trust Sanger Institute